Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging

Area of Science:

• Pharmacology
• Analytical Chemistry
• Oncology

Background:

• Increasing demands for patient safety and drug efficacy drive novel drug development.
• Accurate drug characterization is crucial for demonstrating specificity and selectivity.
• Matrix-assisted laser desorption ionization-mass spectrometry imaging (MALDI-MSI) offers a method for studying drug localization in tissues.

Purpose of the Study:

• To investigate the microenvironmental localization of pharmaceutical drugs within human lung tumor and rat xenograft tissues.
• To characterize the distribution patterns of specific drugs, including epidermal growth factor receptor antagonists (erlotinib, gefitinib) and an acetylcholine receptor antagonist (tiotropium).
• To propose and apply MALDI-MSI models for measuring drug disposition in lung cancer patient tumors.

Main Methods:

• Thin sections and intact tissue blocks of human lung tumors and rat xenografts were exposed to drugs (erlotinib, gefitinib, tiotropium) via spotting, submerging, or immersion.
• Drug localization was analyzed using matrix-assisted laser desorption ionization-mass spectrometry imaging (MALDI-MSI).
• A Thermo MALDI LTQ Orbitrap XL instrument was utilized for high-resolution drug distribution mapping.

Main Results:

• MALDI-MSI successfully localized the distribution patterns of erlotinib, gefitinib, and tiotropium within tissue compartments.
• The study demonstrated the capability of MALDI-MSI to map drug disposition in complex biological matrices.
• Three distinct MALDI-MSI models were developed and applied to analyze drug distribution in lung cancer patient tumors.

Conclusions:

• MALDI-MSI is a powerful tool for characterizing drug localization and disposition in tumor microenvironments.
• This imaging technique provides valuable data for assessing drug specificity and selectivity in preclinical and clinical settings.
• The developed MALDI-MSI models can aid in optimizing drug development and improving therapeutic outcomes in lung cancer treatment.